FDA Clearance Tracker · P990081-S035
PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
Last checked: Nov 20, 2026Latest source record: Mar 13, 2017 (this decision)Source: openFDAMethods & limitations
Decided
Mar 13, 2017
Approved
Time to decision
118 days
Received Nov 15, 2016. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P990081-S035
- Device name
- PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Primary Antibody
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Nov 15, 2016
- Decided
- Mar 13, 2017
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P990081
Device type
- Device type
- SYSTEM, TEST, HER-2/NEU, IHC (MVC)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for software modification in the BenchMark XT from NexES to VSS 12.5 and associated hardware changes.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.